WO2002094173A3 - Tamper resistant oral dosage form - Google Patents
Tamper resistant oral dosage form Download PDFInfo
- Publication number
- WO2002094173A3 WO2002094173A3 PCT/US2002/016269 US0216269W WO02094173A3 WO 2002094173 A3 WO2002094173 A3 WO 2002094173A3 US 0216269 W US0216269 W US 0216269W WO 02094173 A3 WO02094173 A3 WO 02094173A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- oral dosage
- tamper resistant
- resistant oral
- cleavage
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02753331A EP1395224A4 (en) | 2001-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
US10/478,879 US20040156844A1 (en) | 2002-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
AU2002313628A AU2002313628A1 (en) | 2001-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29260301P | 2001-05-22 | 2001-05-22 | |
US60/292,603 | 2001-05-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002094173A2 WO2002094173A2 (en) | 2002-11-28 |
WO2002094173A3 true WO2002094173A3 (en) | 2003-02-20 |
Family
ID=23125385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/016269 WO2002094173A2 (en) | 2001-05-22 | 2002-05-22 | Tamper resistant oral dosage form |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1395224A4 (en) |
AU (1) | AU2002313628A1 (en) |
WO (1) | WO2002094173A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
JP2006515622A (en) * | 2003-01-13 | 2006-06-01 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | Carbohydrate conjugates to prevent the abuse of controlled substances |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US8778382B2 (en) | 2003-04-30 | 2014-07-15 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001166A1 (en) * | 1993-06-30 | 1995-01-12 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
-
2002
- 2002-05-22 WO PCT/US2002/016269 patent/WO2002094173A2/en not_active Application Discontinuation
- 2002-05-22 EP EP02753331A patent/EP1395224A4/en not_active Ceased
- 2002-05-22 AU AU2002313628A patent/AU2002313628A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001166A1 (en) * | 1993-06-30 | 1995-01-12 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
Non-Patent Citations (1)
Title |
---|
See also references of EP1395224A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1395224A4 (en) | 2005-10-26 |
AU2002313628A1 (en) | 2002-12-03 |
EP1395224A2 (en) | 2004-03-10 |
WO2002094173A2 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9925962D0 (en) | Organic compounds | |
MXPA03010007A (en) | Pharmaceutical uses of bisphosphonates. | |
WO2004075736A3 (en) | Aneurysm neck obstruction device | |
ZA200402976B (en) | Electronic pull tab gaming system. | |
WO2000064930A3 (en) | Tribonectins | |
MXPA03006476A (en) | Pharmaceutical dosage forms of epothilones for oral administration. | |
AU2003280087A1 (en) | Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton | |
AU2002352344A1 (en) | Medicament delivery assembly | |
WO2002047668A3 (en) | Novel medicament compositions based on anticholinesterase drugs and on ciclesonides | |
MXPA03010549A (en) | Oxcarbazepine dosage forms. | |
BR0013110A (en) | Oral form of administration containing probiotic microorganisms | |
ZA200305803B (en) | Prevention of diabetes by administration of GnRH antagonists. | |
AU2002352410A1 (en) | Improved oral medicine dispenser | |
BR0314129A (en) | Modified release formulations of oxcarbazepine and derivatives thereof | |
WO2002094173A3 (en) | Tamper resistant oral dosage form | |
WO2001060343A3 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers | |
AU2002317259A1 (en) | Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state | |
HRP20040186B1 (en) | Use of lhrh-antagonists for the improvement of t-cell mediated immunity | |
AUPS286302A0 (en) | Medication inhaler | |
AP2001002369A0 (en) | Pharmaceutical complex. | |
EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration | |
GB0220740D0 (en) | Administration of a system | |
AU2002254930A1 (en) | Novel medicament compositions based on anticholinergic agents and endothelin antagonists | |
AU2002100617A4 (en) | S.A.M. (Self-administering medicine) pacifier | |
AU2003232698A1 (en) | Use of a n,n'-dibenzyl-thiourea as medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10478879 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002753331 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002753331 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |